The article discusses how the success of measles and poliovirus vaccination programs in the U.S. were presenting challenges to maintaining measles antibody potency specifications, and to performing potency tests for polio antibodies. Topics include the challenges being faced in maintaining the potency of Polyclonal immune globulin (IG) products.